EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low Renin and Hypertension

Arian Mansur iD, Anand Vaidya, Alexander Turchin iD

American Journal of Hypertension · 14.07.2023 · 36 (8) · 455-461

DOI: 10.1093/ajh/hpad032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hypertension, online erschienen am 04.04.2023. Verfasst von Arian Mansur und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Hyperaldosteronism, Hypertension. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Mineralocorticoid receptor antagonists (MRAs) are often empirically used for patients with low-renin hypertension (LRH) or probable primary aldosteronism (PA) who decline surgery. However, the optimal approach to MRA therapy is unknown. Studies have shown that a rise in renin is an effective biomarker of prevention of cardiovascular complications of PA. This study aimed to determine whether empiric MRA therapy in patients with LRH or probable PA targeting unsuppressed renin is associated with a decrease in blood pressure and/or proteinuria. METHODS Retrospective single-center cohort study from 2005 to 2021 included adults with LRH or probable PA (renin activity <1.0 ng/ml/h and detectable aldosterone levels). All patients were empirically treated with an MRA, targeting renin ≥1.0 ng/ml/h. RESULTS Out of 39 patients studied, 32 (82.1%) achieved unsuppressed renin. Systolic and diastolic blood pressure decreased from 148.0 and 81.2 to 125.8 and 71.6 mm Hg, respectively (P < 0.001 for both). Similar blood pressure reductions were seen whether patients had high (>10 ng/dl) or low (<10 ng/dl) aldosterone levels. The majority (24/39; 61.5%) of patients had at least one baseline anti-hypertensive medication stopped. Among the six patients who had detectable proteinuria and albumin-to-creatinine (ACR) measurements post-treatment, the mean ACR decreased from 179.0 to 36.1 mg/g (P = 0.03). None of the patients studied had to completely stop treatment due to adverse reactions. CONCLUSIONS Empiric MRA therapy in patients with LRH or probable PA targeting unsuppressed renin can safely and effectively improve blood pressure control and reduce proteinuria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperaldosteronismHypertensionAdultHumansMineralocorticoid Receptor AntagonistsReninAldosteroneMineralocorticoidsRetrospective StudiesCohort Studies

Stichwörter der Autor:innen

blood pressurehypertensionmineralocorticoid receptor antagonistprimary aldosteronismproteinuriarenin

Substanzen

Mineralocorticoid Receptor AntagonistsReninAldosteroneMineralocorticoids

Autor:innen und Institutionen

  • Division of Endocrinology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Arian Mansur, Alexander Turchin

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Mansur, A., Vaidya, A., & Turchin, A. (2023). Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low Renin and Hypertension. American Journal of Hypertension, 36(8), 455-461. https://doi.org/10.1093/ajh/hpad032

Vancouver

Mansur A, Vaidya A, Turchin A. Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low Renin and Hypertension. American Journal of Hypertension. 2023;36(8):455-461. doi:10.1093/ajh/hpad032

BibTeX
@article{Mansur2023,
  author = {Mansur, Arian and Vaidya, Anand and Turchin, Alexander},
  title = {Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low Renin and Hypertension},
  journal = {American Journal of Hypertension},
  year = {2023},
  volume = {36},
  number = {8},
  pages = {455--461},
  doi = {10.1093/ajh/hpad032}
}
Kostenlos starten →